1338540-63-8

Basic information

• Product Name: OTS514
• Synonyms: 9-[4-[(1R)-2-Amino-1-methylethyl]phenyl]-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one
• CAS NO: 1338540-63-8
• Molecular Formula: C21H20N2O2S
• Molecular Weight: 364.4607
• EINECS: 604-604-1
• Mol File: 1338540-63-8.mol

Chemical Properties

• Boiling Point: 501.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.293±0.06 g/cm3(Predicted)
• PKA: 9.35±0.20(Predicted)
• CAS DataBase Reference: OTS514(CAS DataBase Reference)
• NIST Chemistry Reference: OTS514(1338540-63-8)
• EPA Substance Registry System: OTS514(1338540-63-8)

Safety Data

• Hazardous Substances Data: 1338540-63-8(Hazardous Substances Data)

Usage

Uses

Used in Anticancer Applications:
OTS514 is used as an anticancer agent for its ability to inhibit TOPK, a protein kinase involved in cancer cell proliferation and cancer stem cell maintenance. By targeting TOPK, OTS514 can potentially suppress tumor growth and reduce the self-renewal capacity of cancer stem cells, which are responsible for therapy resistance and tumor recurrence.
Additionally, OTS514 is used for its downregulation of the oncogenic transcriptional factor FOXM1. This downregulation can lead to the disruption of cancer cell proliferation and the prevention of tumor progression, making OTS514 a valuable compound in the development of novel cancer therapies.
Used in Drug Development:
In the pharmaceutical industry, OTS514 is used as a lead compound for the development of new cancer treatments. Its dual action as a TOPK inhibitor and FOXM1 downregulator makes it an attractive candidate for the creation of targeted therapies that can specifically address the underlying molecular mechanisms of cancer, potentially leading to more effective and less toxic treatments for patients.
Used in Research:
OTS514 is also used as a research tool in the field of oncology to better understand the molecular mechanisms underlying cancer cell proliferation and cancer stem cell maintenance. By studying the effects of OTS514 on these processes, researchers can gain valuable insights into the development of new therapeutic strategies and the identification of potential targets for cancer treatment.

Relevant articles and documents

TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME

Trycyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.